Stockscreener 앱 받기
16.91
0.47%
-0.08
시간 외 거래:
16.91
전일 마감가:
$16.99
열려 있는:
$16.94
하루 거래량:
395.73K
Relative Volume:
0.87
시가총액:
$6.03B
수익:
$5.21B
순이익/손실:
$-211.00M
주가수익비율:
-27.37
EPS:
-0.6179
순현금흐름:
$861.30K
1주 성능:
+4.58%
1개월 성능:
+2.11%
6개월 성능:
+1.26%
1년 성능:
+24.06%
1일 변동 폭
$16.39
$16.94
1주일 범위
$15.64
$17.01
52주 변동 폭
$13.20
$18.91
Bausch Lomb Corp Stock (BLCO) Company Profile
명칭
Bausch Lomb Corp
전화
908-541-5456
주소
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
16.91 | 5.80B | 5.21B | -211.00M | 861.30K | -0.6179 |
ISRG
Intuitive Surgical Inc
|
353.33 | 127.84B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
165.70 | 43.79B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
68.94 | 32.81B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
39.28 | 33.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
211.00 | 29.46B | 5.54B | 1.52B | 1.74B | 10.37 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-10-01 | 개시 | Goldman | Neutral |
| 2025-05-02 | 재확인 | H.C. Wainwright | Buy |
| 2025-03-28 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-15 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-07-10 | 개시 | Raymond James | Outperform |
| 2024-05-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-01-04 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-12-12 | 개시 | Stifel | Hold |
| 2023-10-03 | 재개 | Evercore ISI | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-03-09 | 개시 | Needham | Hold |
| 2022-12-21 | 개시 | Barclays | Equal Weight |
| 2022-09-12 | 개시 | H.C. Wainwright | Buy |
| 2022-07-26 | 개시 | RBC Capital Mkts | Outperform |
| 2022-06-24 | 개시 | Evercore ISI | Outperform |
| 2022-06-06 | 개시 | Citigroup | Buy |
| 2022-05-31 | 개시 | Deutsche Bank | Hold |
| 2022-05-31 | 개시 | Goldman | Neutral |
| 2022-05-31 | 개시 | Guggenheim | Buy |
| 2022-05-31 | 개시 | JP Morgan | Neutral |
| 2022-05-31 | 개시 | Jefferies | Buy |
| 2022-05-31 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 개시 | Wells Fargo | Overweight |
| 2022-05-11 | 개시 | Cowen | Outperform |
모두보기
Bausch Lomb Corp 주식(BLCO)의 최신 뉴스
Bausch + Lomb earnings up next: Can growth offset pipeline loss? - Investing.com
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Bausch + Lomb Corp (BLCO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BLCO|Bausch + Lomb Corp|Price:16.260|Chg%:+0.090 - TradingKey
Bausch + Lomb Corporation Revenue Breakdown – MUN:S2L - TradingView
Bausch + Lomb Corp (BLCO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Investor Outlook: Bausch + Lomb Corporation (BLCO) Eyes 12% Upside Potential Amid Steady Growth - DirectorsTalk Interviews
Bausch + Lomb Corp (BLCO) Balance Sheet - TradingKey
Bausch + Lomb Corp (BLCO) Cash Flow - TradingKey
Bausch + Lomb Corp (BLCO) Income Statement - TradingKey
Bausch + Lomb Corp (BLCO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bausch + Lomb Corp (BLCO) Institutional Confidence - TradingKey
BLCO|Bausch + Lomb Corp|Price:16.170|Chg%:+0.210 - TradingKey
Bausch + Lomb Corporation (BLCO) Gets a Hold from Wells Fargo - The Globe and Mail
BLCO Forecast — Price Target — Prediction for 2027 - TradingView
3 Reasons to Avoid BLCO and 1 Stock to Buy Instead - Yahoo Finance
Bausch + Lomb launches EyeGility preloaded IOL delivery system in US - Ophthalmology Times Europe
Bausch + Lomb launches EyeGility inserter for enVista IOLs in the US - MSN
Bausch Health Companies stock hits 52-week low at $4.56 By Investing.com - Investing.com South Africa
Bausch Health Companies stock hits 52-week low at $4.56 - Investing.com
Bausch + Lomb launches EyeGility Inserter to streamline cataract lens delivery in US - Indian Pharma Post
BHC5652799 Bond Profile — Key Metrics - TradingView
Bausch + Lomb Launches the EyeGility Inserter Preloaded IOL Delivery System - VisionMonday.com
Bausch + Lomb launches AI-powered digital health platform By Investing.com - Investing.com Nigeria
Bausch + Lomb's Prescription Drug Growth Could Support Q2 Results, RBC Says - Moomoo
RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Bausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S. - Yahoo Finance
Bausch + Lomb Corporation (BLCO) Stock Analysis: Eyeing A Potential 11.54% Upside - DirectorsTalk Interviews
Bausch + Lomb (BLCO) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure - Stocktwits
(BLCO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Intellia Therapeutics (NTLA) - The Globe and Mail
Bausch + Lomb launches EyeGility IOL delivery system in U.S. By Investing.com - Investing.com Australia
Bausch + Lomb's BL1107 falls short in phase 2 glaucoma trial, redirects program toward geographic atrophy implant - Ophthalmology Times Europe
Bausch + Lomb Launches EyeGility Inserter Preloaded IOL Delivery System In The United States - marketscreener.com
Bausch + Lomb launches EyeGility IOL delivery system in U.S. - Investing.com
Bausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United States - Business Wire
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $21 - Moomoo
(BLCO) Equity Market Report (BLCO:CA) - Stock Traders Daily
Bausch + Lomb's BL1107 fails primary end point in Phase 2 glaucoma trial - Optometry Times
Ophthalmology Devices Market Report Released, Includes - GlobeNewswire
Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others - Yahoo Finance UK
Bausch + Lomb Corporation (BLCO) Stock Analysis: Examining a Healthcare Leader with 11.68% Potential Upside - DirectorsTalk Interviews
(BLCO) Technical Pivots with Risk Controls (BLCO:CA) - Stock Traders Daily
Bausch + Lomb abandons glaucoma drops after phase 2 failure - MSN
Bausch + Lomb ditches BL1107 in glaucoma after trial miss - The Pharma Letter
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today - Yahoo Finance
Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus - Benzinga
Bausch + Lomb Introduces Orphia, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care - marketscreener.com
Price to earnings forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Price to sales forward of Bausch + Lomb Corporation – NYSE:BLCO - TradingView
Bausch Lomb Corp (BLCO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bausch Lomb Corp 주식 (BLCO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Eldessouky Sam | EVP and CFO |
Mar 06 '26 |
Buy |
17.13 |
4,000 |
68,520 |
403,130 |
| SAUNDERS BRENT L | CEO and Chairman of the Board |
Mar 06 '26 |
Buy |
17.14 |
14,700 |
251,958 |
966,575 |
| Ross Thomas W. Sr. | Director |
Mar 03 '26 |
Buy |
17.68 |
4,500 |
79,556 |
64,891 |
| Alfonso Eduardo | Director |
Mar 02 '26 |
Buy |
17.90 |
4,300 |
76,970 |
9,555 |
| VON ESCHENBACH ANDREW C. | Director |
Feb 27 '26 |
Buy |
18.30 |
4,364 |
79,883 |
66,450 |
| COLLIS STEVEN H | Director |
Feb 23 '26 |
Buy |
17.81 |
15,000 |
267,150 |
20,255 |
| ROBERTSON RUSSEL C | Director |
Feb 20 '26 |
Buy |
17.90 |
4,400 |
78,760 |
72,407 |
| Ling Karen | Director |
Feb 19 '26 |
Buy |
17.74 |
4,000 |
70,968 |
41,676 |
2.49%
0.42%
자본화:
|
볼륨(24시간):